Unlocking the Potential of Ribosomal Protein S12 Pseudogene 23 as a Drug Target or Biomarker

Target Name: RPS12P23

NCBI ID: G338870

RPS12P23

Other Name(s): ribosomal protein S12 pseudogene 23 | RPS12_11_1301 | Ribosomal protein S12 pseudogene 23

Unlocking the Potential of Ribosomal Protein S12 Pseudogene 23 as a Drug Target or Biomarker

Ribosomal protein S12 pseudogene 23 (RPS12P23) is a non-coding RNA molecule that plays a critical role in the regulation of gene expression in eukaryotic cells. RPS12P23 is a key regulator of the poly(A)/ribosome complex, which is responsible for the translation of mRNAs into proteins. The RPS12P23 gene has been well conserved across various species, and its function is highly conserved from yeast to humans.

Recent studies have identified RPS12P23 as a potential drug target or biomarker in various diseases, including cancer, neurodegenerative diseases, and chronic diseases. In this article, we will explore the potential of RPS12P23 as a drug target or biomarker and discuss the current research on this topic.

Potential Drug Target

RPS12P23 has been identified as a potential drug target due to its unique function in the regulation of gene expression. RPS12P23 plays a critical role in the regulation of the poly(A)/ribosome complex, which is responsible for the translation of mRNAs into proteins. The RPS12P23 gene has been shown to regulate the activity of several key enzymes involved in the poly(A)/ribosome complex, including the RNA polymerase II (RNA-pro) and the splicing machinery.

Studies have shown that inhibiting the activity of RPS12P23 can lead to the accumulation of misfolded RNA in the cytoplasm, which can lead to the formation of aggregates and the development of various diseases, including cancer. Therefore, RPS12P23 has been identified as a potential drug target for cancer treatment.

Potential Biomarker

RPS12P23 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic diseases. The RPS12P23 gene has been shown to be expressed in a variety of tissues and cells, including cancer cells, neurodegenerative diseases, and heart failure cells.

Studies have shown that the expression of RPS12P23 is significantly increased in various diseases, including cancer, neurodegenerative diseases, and chronic diseases. Therefore, RPS12P23 has been identified as a potential biomarker for these diseases.

Current Research

RPS12P23 has been studied extensively in the past, and many studies have shown its potential as a drug target or biomarker. Some studies have shown that inhibiting the activity of RPS12P23 can lead to the accumulation of misfolded RNA in the cytoplasm, which can lead to the formation of aggregates and the development of various diseases, including cancer.

Other studies have shown that RPS12P23 is expressed in a variety of tissues and cells, including cancer cells, neurodegenerative diseases, and heart failure cells. Therefore, RPS12P23 has been identified as a potential biomarker for these diseases.

Conclusion

Ribosomal protein S12 pseudogene 23 (RPS12P23) has been identified as a potential drug target or biomarker due to its unique function in the regulation of gene expression. The RPS12P23 gene has been shown to regulate the activity of several key enzymes involved in the poly(A)/ribosome complex, and it has also been shown to be expressed in a variety of tissues and cells, including cancer cells, neurodegenerative diseases, and heart failure cells.

Therefore, RPS12P23 has the potential to be a valuable drug target or biomarker for various diseases, including cancer, neurodegenerative diseases, and chronic diseases. Further research is needed to fully understand the function of RPS12P23 and its potential as a drug

Protein Name: Ribosomal Protein S12 Pseudogene 23

The "RPS12P23 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about RPS12P23 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets